{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:46Z","timestamp":1790812126679,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Australian Government Research Training Program"},{"name":"Australian National Health and Medical Research Council Investigator Grant","award":["1174523"],"award-info":[{"award-number":["1174523"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes and mortality in type 2 diabetes mellitus after 5\u00a0years of active treatment. However, a beneficial reduction in major CVD events was shown in a pre-specified sub-group of participants with dyslipidemia. The extended follow-up of this trial provides the opportunity to further investigate possible beneficial effects of fibrates in this group of patients. We aimed to evaluate possible \u201clegacy effects\u201d of fibrate add-on therapy on mortality and major cardiovascular outcomes in patients with dyslipidemia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The ACCORD-lipid study was a randomized controlled trial of 5518 participants assigned to receive simvastatin plus fenofibrate vs simvastatin plus placebo. After randomized treatment allocation had finished at the end of the trial, all surviving participants were invited to attend an extended follow-up study (ACCORDION) to continue prospective collection of clinical outcomes. We undertook a secondary analysis of trial and post-trial data in patients who had dyslipidemia. The primary outcome was all-cause and cardiovascular mortality, and secondary outcomes were nonfatal myocardial infarction, stroke, congestive heart failure and major coronary heart disease. We used an intention-to-treat approach to analysis to make comparisons between the original randomized treatment groups.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>853 participants with dyslipidemia had survived at the end of the trial. Most participants continued to use statins, but few used fibrates in either group during the post-trial period. The incidence rates in the fenofibrate group were lower with respect to all-cause mortality, CVD mortality, nonfatal myocardial infarction, congestive heart failure and major coronary heart disease than those in the placebo group over a post-trial follow-up. Allocation to the combined fibrate-statin treatment arm during the trial period had a beneficial legacy effect on all-cause mortality (adjusted HR\u2009=\u20090.65, 95% CI 0.45\u20130.94; <jats:italic>P<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Fibrate treatment during the initial trial period was associated with a legacy benefit of improved survival over a post-trial follow-up. These findings support re-evaluation of fibrates as an add-on strategy to statins in order to reduce cardiovascular risk in diabetic patients with dyslipidemia.<\/jats:p>\n<jats:p><jats:italic>Trial registration<\/jats:italic> clinicaltrials.gov, Identifier: NCT00000620<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12933-020-01002-x","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T13:02:52Z","timestamp":1583413372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study"],"prefix":"10.1186","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct00000620","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6883-5176","authenticated-orcid":false,"given":"Lin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy J. L.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"1002_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/ncpendmet1066","volume":"5","author":"AD Mooradian","year":"2009","unstructured":"Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:150\u20139.","journal-title":"Nat Rev Endocrinol"},{"key":"1002_CR2","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73:e285\u2013350. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003.","journal-title":"J Am Coll Cardiol"},{"key":"1002_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11892-019-1136-3","volume":"19","author":"A-S Alexopoulos","year":"2019","unstructured":"Alexopoulos A-S, Qamar A, Hutchins K, Crowley MJ, Batch BC, Guyton JR. Triglycerides: emerging targets in diabetes care? Review of moderate hypertriglyceridemia in diabetes. Curr Diabetes Rep. 2019;19:13. https:\/\/doi.org\/10.1007\/s11892-019-1136-3.","journal-title":"Curr Diabetes Rep"},{"key":"1002_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"CT Trialists","year":"2008","unstructured":"Trialists CT. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117\u201325.","journal-title":"Lancet"},{"key":"1002_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"CT Trialists","year":"2005","unstructured":"Trialists CT. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267\u201378.","journal-title":"Lancet"},{"key":"1002_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","volume":"376","author":"PM Ridker","year":"2010","unstructured":"Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(10)60713-1.","journal-title":"Lancet"},{"key":"1002_CR7","doi-asserted-by":"publisher","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","volume":"102","author":"J-C Fruchart","year":"2008","unstructured":"Fruchart J-C, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102:1K\u201334K.","journal-title":"Am J Cardiol"},{"key":"1002_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","volume":"14","author":"UK Sampson","year":"2012","unstructured":"Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1\u201310. https:\/\/doi.org\/10.1007\/s11883-011-0219-7.","journal-title":"Curr Atheroscler Rep"},{"key":"1002_CR9","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.115.018580","volume":"133","author":"WE Hague","year":"2016","unstructured":"Hague WE, Simes J, Kirby A, Keech AC, White HD, Hunt D, et al. Long-term effectiveness and safety of pravastatin in patients with coronary heart disease. Circulation. 2016;133:1851\u201360. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018580.","journal-title":"Circulation"},{"key":"1002_CR10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623\u201330.","journal-title":"Lancet"},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"R Collins","year":"2002","unstructured":"Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360:7\u201322.","journal-title":"Lancet"},{"key":"1002_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003008.","journal-title":"Circulation"},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1373\/clinchem.2013.219881","volume":"60","author":"M Thomsen","year":"2014","unstructured":"Thomsen M, Varbo A, Tybjaerg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin Chem. 2014;60:737\u201346. https:\/\/doi.org\/10.1373\/clinchem.2013.219881.","journal-title":"Clin Chem"},{"key":"1002_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","volume":"36","author":"MV Holmes","year":"2015","unstructured":"Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36:539\u201350.","journal-title":"Eur Heart J"},{"key":"1002_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/11207690-000000000-00000","volume":"11","author":"GM Keating","year":"2011","unstructured":"Keating GM. Fenofibrate. Am J Cardiovasc Drugs. 2011;11:227\u201347. https:\/\/doi.org\/10.2165\/11207690-000000000-00000.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"E Pisano","year":"2010","unstructured":"Pisano E, Gatsonis C, Boineau R, Domanski M, Troutman C, Anderson J, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1001282.","journal-title":"N Engl J Med"},{"key":"1002_CR17","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2337\/dc13-2334","volume":"37","author":"KL Margolis","year":"2014","unstructured":"Margolis KL, O\u2019Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721\u20138. https:\/\/doi.org\/10.2337\/dc13-2334.","journal-title":"Diabetes Care"},{"key":"1002_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","volume":"57","author":"E Bruckert","year":"2011","unstructured":"Bruckert E, Labreuche J, Deplanque D, Touboul P-J, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011;57:267\u201372.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1002_CR19","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(10)60656-3.","journal-title":"Lancet"},{"key":"1002_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","volume":"217","author":"M Lee","year":"2011","unstructured":"Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.04.020.","journal-title":"Atherosclerosis"},{"key":"1002_CR21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2337\/dc17-0968","volume":"41","author":"C Koopal","year":"2018","unstructured":"Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC. Predicting the effect of fenofibrate on cardiovascular risk for individual patients with type 2 diabetes. Diabetes Care. 2018;41:1244\u201350. https:\/\/doi.org\/10.2337\/dc17-0968.","journal-title":"Diabetes Care"},{"key":"1002_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jclinepi.2019.05.010","volume":"114","author":"L Zhu","year":"2019","unstructured":"Zhu L, Bell KJL, Hayen A. Estimated legacy effects from simulated post-trial data were less biased than from combined trial\/post-trial data. J Clin Epidemiol. 2019;114:30\u20137. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.05.010.","journal-title":"J Clin Epidemiol"},{"key":"1002_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5125","author":"NH Kim","year":"2019","unstructured":"Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l5125.","journal-title":"BMJ"},{"key":"1002_CR24","doi-asserted-by":"publisher","DOI":"10.21542\/gcsp.2016.35","author":"MA Kashef","year":"2017","unstructured":"Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract. 2017. https:\/\/doi.org\/10.21542\/gcsp.2016.35.","journal-title":"Glob Cardiol Sci Pract"},{"key":"1002_CR25","doi-asserted-by":"publisher","first-page":"e020584","DOI":"10.1136\/bmjopen-2017-020584","volume":"8","author":"A Nayak","year":"2018","unstructured":"Nayak A, Hayen A, Zhu L, McGeechan K, Glasziou P, Irwig L, et al. Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open. 2018;8:e020584. https:\/\/doi.org\/10.1136\/bmjopen-2017-020584.","journal-title":"BMJ Open"},{"key":"1002_CR26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1006524","volume":"364","author":"HC Gerstein","year":"2011","unstructured":"ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818\u201328.","journal-title":"N Engl J Med"},{"key":"1002_CR27","unstructured":"ACCORDION: the ACCORD follow-on study. 2011. https:\/\/biolincc.nhlbi.nih.gov\/media\/studies\/accord\/ACCORDION_Protocol.pdf."},{"key":"1002_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","volume":"2","author":"MB Elam","year":"2017","unstructured":"Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2:370. https:\/\/doi.org\/10.1001\/jamacardio.2016.4828.","journal-title":"JAMA Cardiol"},{"key":"1002_CR29","first-page":"464","volume":"114","author":"P Malur","year":"2017","unstructured":"Malur P, Menezes A, DiNicolantonio JJ, O\u2019Keefe JH, Lavie CJ. The microvascular and macrovascular benefits of fibrates in diabetes and the metabolic syndrome: a review. Mo Med. 2017;114:464\u201371.","journal-title":"Mo Med"},{"key":"1002_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144\u201352. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.032.","journal-title":"Atherosclerosis"},{"key":"1002_CR31","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"T Field","year":"2005","unstructured":"Field T. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849\u201361.","journal-title":"Lancet"},{"key":"1002_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-019-0845-x","volume":"18","author":"S Ida","year":"2019","unstructured":"Ida S, Kaneko R, Murata K. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18:38. https:\/\/doi.org\/10.1186\/s12933-019-0845-x.","journal-title":"Cardiovasc Diabetol"},{"key":"1002_CR33","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0563","author":"S Park","year":"2019","unstructured":"Park S, Lee S, Kim Y, Lee Y, Kang MW, Han K, et al. Altered risk for cardiovascular events with changes in the metabolic syndrome status. Ann Intern Med. 2019. https:\/\/doi.org\/10.7326\/M19-0563.","journal-title":"Ann Intern Med"},{"key":"1002_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018;206:80\u201393. https:\/\/doi.org\/10.1016\/j.ahj.2018.09.011.","journal-title":"Am Heart J"},{"key":"1002_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0864-7","author":"JC Fruchart","year":"2019","unstructured":"Fruchart JC, Santos RD, Salinas CA, Aikawa M, Al Rasadi K, Amarenco P, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: conceptual framework and therapeutic potential. Cardiovasc Diabetol. 2019. https:\/\/doi.org\/10.1186\/s12933-019-0864-7.","journal-title":"Cardiovasc Diabetol"},{"key":"1002_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176\u201386.","journal-title":"Lancet"},{"key":"1002_CR37","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/978-3-662-48986-4_2226","volume":"285","author":"Expert Panel on Detection, Evaluation and T of HBC in A","year":"2001","unstructured":"Expert Panel on Detection, Evaluation and T of HBC in A. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA J Am Med Assoc. 2001;285:2486\u201397. https:\/\/doi.org\/10.1007\/978-3-662-48986-4_2226.","journal-title":"JAMA J Am Med Assoc"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01002-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01002-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01002-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:18:35Z","timestamp":1628612315000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01002-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01002-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"6 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We received ethical approval from UTS Human Research Ethics Committee (ETH18-2736). Written informed consent for participation in the study was obtained from all the subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}